Lecithin) Biosynthesis in Rat Brain Neurons (Phospholipid/N-Methylation/Synaptosomes/Catecholamines/Norepinephrine) CAROL E

Total Page:16

File Type:pdf, Size:1020Kb

Lecithin) Biosynthesis in Rat Brain Neurons (Phospholipid/N-Methylation/Synaptosomes/Catecholamines/Norepinephrine) CAROL E Proc. Natl Acad. Sci. USA Vol. 80, pp. 2063-2066, April 1983 Neurobiology Dopamine stimulation of phosphatidylcholine (lecithin) biosynthesis in rat brain neurons (phospholipid/N-methylation/synaptosomes/catecholamines/norepinephrine) CAROL E. LEPROHON, JAN K. BLUSZTAJN, AND RICHARD J. WURTMAN* Laboratory of Neuroendocrine Regulation, Department of Nutrition and Food Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 Communicated by Julius Axelrod, October 18, 1982 ABSTRACT Rat brain synaptosomes contain enzymes, phos- nuclei. The supernatant was layered on top of 4 ml of 1.2 M phatidylethanolamine N-methyltransferase(s) (EC 2.1.1.17), that sucrose and centrifuged at 165,000 X -g for 15 min in a Beck- catalyze the methylation of endogenous phosphatidylethanol- man SW 41 Ti rotor. The resulting pellet contained mito- amine to form its mono-, di-, and trimethyl (i.e., phosphatidyl- chondria; the material at the interface of the gradient (con- choline) derivatives. We observe that the activity of these en- taining the synaptosomes and myelin) was diluted to obtain zymes is enhanced when synaptosomes are incubated with cat- approximately 0.32 M sucrose, layered on top of 4 ml of 0.8 echolamines: 0.1 mM dopamine increases incorporation of [3H]- M sucrose, and centrifuged at 165,000 X g for 15 min (17). methyl groups into monomethylphosphatidylethanolamine, di- The material at the interface, containing myelin, and the pel- methylphosphatidylethanolamine, and phosphatidylcholine by let, shown to contain synaptosomes by electron factors of 1.7, 1.3, and 2.1, respectively, and 0.1 mM norepi- microscopy, nephrine increases [3H]methyl incorporation into monomethyl- were collected. In some cases, the postnuclear supernatant phosphatidylethanolamine and dimethylphosphatidylethanol- was centrifuged at 20,000 x g for 20 min to obtain the P2 pel- amine by factors of 1.6 and 2.1, respectively. Stimulation by let (containing synaptosomes, mitochondria, and myelin). The dopamine, which is observed at concentrations as low as 1 ,IM, post-P2 supernatant was centrifuged at 100,000 X g for 60 min is blocked by haloperidol. to obtain a microsomal pellet. PtdEtnMeTase Assay. PtdEtnMeTase activity was assayed Synaptosomal membranes from rat (1-3) and bovine (4, 5) brain by a modification of the method described previously (4). The contain an enzyme, or enzymes, phosphatidylethanolamine N- standard assay medium was changed to 50 mM Tris HCl, pH methyltransferase(s) (PtdEtnMeTase; EC 2.1.1.17) that en- 7.5/5 mM MgCl2/0.2 mM EDTA/0. 1 mM ATP and tissue ables them to synthesize phosphatidylcholine (PtdCho) by the preparation (0.2-0.4 mg of protein) in a final volume of 120 stepwise methylation of phosphatidylethanolamine (PtdEtn), 1.l. The effect on phospholipid [3Himethyl incorporation of using S-adenosylmethionine (AdoMet) as the methyl donor. omitting various components of this medium was examined Part of this newly synthesized PtdCho is hydrolyzed to lib- (see Table 1). Norepinephrine-HCI (Sigma), dopamineHCl erate free choline (1), which might be available for acetyl- (Sigma), haloperidol lactate (5 mg/ml, containing 1.8 mg of choline synthesis; part may be retained as a constituent of cel- methylparaben and 0.2 mg of propylparaben; a gift from lular membranes. PtdEtnMeTases in various tissues have been McNeil, Fort Washington, PA), were added to some tubes shown to be activated by such receptor agonists as catechol- before incubation. Reactions were started by addition of 2.5 amines [rat reticulocytes (6, 7), C6 glioma astrocytoma (8), jCi of S-adenosyl[methyl-3H]methionine (New England Nu- lymphocytes (9)], lectins [lymphocytes (10), mast cells (11)], clear; 13-15 Ci/mmol; 1 Ci = 37 GBq) to a final AdoMet con- immunoglobulins [mast cells (12), leukemic basophils (13)], centration of 1.2-1.6 ,uM. Samples were incubated for 30 min glucagon [hepatocytes (14)]., vasopressin [pituitary extracts (15), at 37TC. Reactions were stopped by addition of 3 ml of chlo- hepatocytes (16)], and angiotensin [hepatocytes (16)]. This roform/methanol/HCI, 100:50:1 (vol/vol). Water-soluble ra- process is rapid and not dependent on cAMP synthesis. Little dioactive. materials were extracted by washing the incubation information has been available on the control of PtdEtn- mixture with two 2-ml portions of 0.75% KCI in 50% meth- MeTase activity within brain neurons. We report here that anol. catecholamine neurotransmitters, especially dopamine, en- The chloroform phase was taken to dryness in a Savant Speed- hance the activities of phosph6lipid methylating enzymes in Vac lyophilizing centrifuge, and the [3H]phospholipids were rat brain synaptosomes. suspended in 50 p.1 of chloroform/methanol, 1:1 (vol/vol). The [3H]phospholipids, together with phosphatidylmono- METHODS methylethanolamine (PtdMeEtn), phosphatidyldimethyletha- Preparation of Subcellular Fractions. Male Sprague-Daw- nolamine (PtdMe2Etn), and PtdCho standards, were applied ley rats (200-300 g; Charles River Breeding Laboratories) were to silica gel TLC plates (Silica gel G; Absorbosil Plus, Applied housed under a 12-hr/12-hr light/dark schedule (lights on, Science Division, State College, PA) and the chromatogram 0900-2100 hr) and had free access to water and food (Charles was developed in chloroform/propionic acid/n-propanol/water, River chow; 22% protein, 0.018% choline). The animals were 2:2:3:1 (vol/vol) (4). Compounds were visualized with di- decapitated at 1000 hr, and the brains were quickly dissected on ice and homogenized in 10 vol of 0.32 M sucrose in a Pot- Abbreviations: PtdCho, phosphatidylcholine; PtdEtn, phosphatidyl- ter-Elvehjem homogenizer; the homogenate was then cen- ethanolamine; PtdEtnMeTase, phosphatidylethanolamine N-methyl- transferase; PtdMe2Etn, phosphatidyldimethylethanolamine; Ptd- trifuged at 1,000 x g for 15 min to remove tissue debris and MeEtn, phosphatidylmonomethylethanolamine; AdoMet, S-adenosyl- methionine; Bt2cAMP, N6,02-dibutyryladenosine 3',5'-cyclic mono- The publication costs of this article were defrayed in part by page charge phosphate. payment. This article must therefore be hereby marked "advertise- *To whom reprint requests should be addressed at: Room E25-604, ment" in accordance with 18 U. S. C. §1734 solely to indicate this fact. M.I.T., Cambridge, MA 02139. 2063 Downloaded by guest on October 2, 2021 2064 Neurobiology: Leprohon et al. Proc. Natl. Acad. Sci. USA 80 (1983) phenylhexatriene (10 mg/100 ml of petroleum ether; ref. 18) PtdEtnMeTase activity by dopamine (Table 1); tubes were in- and the silica was then scraped into scintillation vials. The newly cubated with or without dopamine, Mg2+, ATP, or phospho- formed [3H]phospholipids were eluted with 1 ml of methanol, lipid substrates. In most situations, dopamine markedly en- 15 ml of Betafluor (National Diagnostics, Somerville, NJ) was hanced the incorporation of [3H]methyl into PtdMeEtn, added to each vial, and the radioactivity of the samples was PtdMe2Etn, and PtdCho. Mg2+ alone increased both basal and determined. Efficiency of assay for 3H was =50%. Recovery dopamine-stimulated [3H]phospholipid accumulation. ATP, of [3H]phospholipids was =70%. added alone or with Mg2+, lacked a consistent effect on [3H]- To ensure that the methods used for assessing [31H]methyl phospholipid synthesis; in some experiments the combination incorporation correctly identified the various [3H]phospholip- of ATP and Mg2+ enhanced basal Ptd[3H]MeEtn and Ptd[3H]- id fractions, we analyzed both the fractions themselves (from Me2Etn syntheses while in others it did not. Addition of phos- basal and catecholamine-stimulated samples) and their [3H]base pholipid substrates tended to enhance the accumulation of all contents after hydrolysis. The [3H]phospholipids were sepa- three [3H]phospholipids, both in the presence and in the ab- rated by two-dimensional TLC using chloroform/methanol/ sence of dopamine. Since the phospholipids added did not acetic acid, 65:30:5 (vol/vol) in the first dimension and chlo- include PtdEtn, the enhanced accumulation of Ptd[3H]MeEtn roform/methanol/2-propanol/0.25% KCI/triethylamine, 30: probably reflected a slowing in its further metabolism. The 9:25:6:18 (vol/vol) (19) in the second dimension; they were addition of phospholipid substrates to the incubation mixture then scraped from the TLC plate and their radioactivities were did not further enhance determined. Although the triethylamine system results in bet- the effect of dopamine on Ptd- ter separation of the [3H]phospholipids than the propionic acid EtnMeTase. In subsequent experiments, we assayed Ptd- system, the dopamine metabolites homovanillic acid and 4-hy- EtnMeTase activity in the presence of Mg2+ and ATP and droxy-3-methoxyphenylethanol were found to comigrate with without PtdMeEtn and PtdMe2Etn to maximize the dopamine PtdMeEtn and PtdMe2Etn, respectively. Hence, triethylamine effect. was not the TLC system of choice for unidirectional chroma- Both dopamine and norepinephrine stimulated PtdEtn tography. Both these dopamine metabolites migrate with the methylation in a dose-dependent fashion (Table 2). The effects solvent front in the propionic acid system. The bases hydrolyzed of dopamine were detectable at concentrations as low as 1 uM from the [3H]phospholipids (by incubation of phospholipid frac- and, in most studies, could be seen with PtdMeEtn, Ptd- tions, separated by routine TLC, in 6 M HCl at 80'C for 1 hr) Me2Etn, and PtdCho; norepinephrine required higher (10 ,uM) were separated by HPLC on a
Recommended publications
  • Role of Citicoline in the Management of Traumatic Brain Injury
    pharmaceuticals Review Role of Citicoline in the Management of Traumatic Brain Injury Julio J. Secades Medical Department, Ferrer, 08029 Barcelona, Spain; [email protected] Abstract: Head injury is among the most devastating types of injury, specifically called Traumatic Brain Injury (TBI). There is a need to diminish the morbidity related with TBI and to improve the outcome of patients suffering TBI. Among the improvements in the treatment of TBI, neuroprotection is one of the upcoming improvements. Citicoline has been used in the management of brain ischemia related disorders, such as TBI. Citicoline has biochemical, pharmacological, and pharmacokinetic characteristics that make it a potentially useful neuroprotective drug for the management of TBI. A short review of these characteristics is included in this paper. Moreover, a narrative review of almost all the published or communicated studies performed with this drug in the management of patients with head injury is included. Based on the results obtained in these clinical studies, it is possible to conclude that citicoline is able to accelerate the recovery of consciousness and to improve the outcome of this kind of patient, with an excellent safety profile. Thus, citicoline could have a potential role in the management of TBI. Keywords: CDP-choline; citicoline; pharmacological neuroprotection; brain ischemia; traumatic brain injury; head injury Citation: Secades, J.J. Role of 1. Introduction Citicoline in the Management of Traumatic brain injury (TBI) is among the most devastating types of injury and can Traumatic Brain Injury. result in a different profile of neurological and cognitive deficits, and even death in the most Pharmaceuticals 2021, 14, 410.
    [Show full text]
  • 4695389.Pdf (3.200Mb)
    Non-classical amine recognition evolved in a large clade of olfactory receptors The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Li, Qian, Yaw Tachie-Baffour, Zhikai Liu, Maude W Baldwin, Andrew C Kruse, and Stephen D Liberles. 2015. “Non-classical amine recognition evolved in a large clade of olfactory receptors.” eLife 4 (1): e10441. doi:10.7554/eLife.10441. http://dx.doi.org/10.7554/ eLife.10441. Published Version doi:10.7554/eLife.10441 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:23993622 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA RESEARCH ARTICLE Non-classical amine recognition evolved in a large clade of olfactory receptors Qian Li1, Yaw Tachie-Baffour1, Zhikai Liu1, Maude W Baldwin2, Andrew C Kruse3, Stephen D Liberles1* 1Department of Cell Biology, Harvard Medical School, Boston, United States; 2Department of Organismic and Evolutionary Biology, Museum of Comparative Zoology, Harvard University, Cambridge, United States; 3Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States Abstract Biogenic amines are important signaling molecules, and the structural basis for their recognition by G Protein-Coupled Receptors (GPCRs) is well understood. Amines are also potent odors, with some activating olfactory trace amine-associated receptors (TAARs). Here, we report that teleost TAARs evolved a new way to recognize amines in a non-classical orientation.
    [Show full text]
  • Clinical Significance of Small Molecule Metabolites in the Blood of Patients
    www.nature.com/scientificreports OPEN Clinical signifcance of small molecule metabolites in the blood of patients with diferent types of liver injury Hui Li1,2,5, Yan Wang1,5, Shizhao Ma1,3, Chaoqun Zhang1,4, Hua Liu2 & Dianxing Sun1,4* To understand the characteristic of changes of serum metabolites between healthy people and patients with hepatitis B virus (HBV) infection at diferent stages of disease, and to provide reference metabolomics information for clinical diagnosis of liver disease patients. 255 patients with diferent stages of HBV infection were selected. 3 mL blood was collected from each patient in the morning to detect diferences in serum lysophosphatidylcholine, acetyl-l-carnitine, oleic acid amide, and glycocholic acid concentrations by UFLC-IT-TOF/MS. The diagnostic values of four metabolic substances were evaluated by receiver operating characteristic (ROC) curve. The results showed that the optimal cut-of value of oleic acid amide concentration of the liver cirrhosis and HCC groups was 23.6 mg/L, with a diagnostic sensitivity of 88.9% and specifcity of 70.6%. The diagnostic efcacies of the three substances were similar in the hepatitis and HCC groups, with an optimal cut-of value of 2.04 mg/L, and a diagnostic sensitivity and specifcity of 100% and 47.2%, respectively. The optimal cut-of value of lecithin of the HBV-carrier and HCC groups was 132.85 mg/L, with a diagnostic sensitivity and specifcity of 88.9% and 66.7%, respectively. The optimal cut-of value of oleic acid amide of the healthy and HCC groups was 129.03 mg/L, with a diagnostic sensitivity and specifcity of 88.4% and 83.3%, respectively.
    [Show full text]
  • Acetylcholine Signaling System in Progression of Lung Cancers
    Pharmacology & Therapeutics 194 (2019) 222–254 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Acetylcholine signaling system in progression of lung cancers Jamie R. Friedman a,1, Stephen D. Richbart a,1,JustinC.Merritta,KathleenC.Browna, Nicholas A. Nolan a, Austin T. Akers a, Jamie K. Lau b, Zachary R. Robateau a, Sarah L. Miles a,PiyaliDasguptaa,⁎ a Department of Biomedical Sciences, Joan C. Edwards School of Medicine, 1700 Third Avenue, Huntington, WV 25755 b Biology Department, Center for the Sciences, Box 6931, Radford University, Radford, Virginia 24142 article info abstract Available online 3 October 2018 The neurotransmitter acetylcholine (ACh) acts as an autocrine growth factor for human lung cancer. Several lines of evidence show that lung cancer cells express all of the proteins required for the uptake of choline (choline Keywords: transporter 1, choline transporter-like proteins) synthesis of ACh (choline acetyltransferase, carnitine acetyl- Lung cancer transferase), transport of ACh (vesicular acetylcholine transport, OCTs, OCTNs) and degradation of ACh (acetyl- Acetylcholine cholinesterase, butyrylcholinesterase). The released ACh binds back to nicotinic (nAChRs) and muscarinic Cholinergic receptors on lung cancer cells to accelerate their proliferation, migration and invasion. Out of all components Proliferation of the cholinergic pathway, the nAChR-signaling has been studied the most intensely. The reason for this trend Invasion Anti-cancer drugs is due to genome-wide data studies showing that nicotinic receptor subtypes are involved in lung cancer risk, the relationship between cigarette smoke and lung cancer risk as well as the rising popularity of electronic ciga- rettes considered by many as a “safe” alternative to smoking.
    [Show full text]
  • Eletriptan Smpc
    For the use only of a neurologist/ specialist or a Hospital or a Laboratory Generic Name Citicoline Trade Name Ceham 1. NAME OF THE MEDICINAL PRODUCT: Citicoline 2. QUALITATIVE AND QUANTITATIVE COMPOSITION: Each film coated tablet contains: Citicoline sodium equivalent to Citicoline……………………………500mg 3. PHARMACEUTICAL FORM: Film coated tablet 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications: For the treatment of disturbance of consciousness as resulting from head injuries, brain operation and acute stage of cerebral infarction in adult only. For the treatment of patients with serious cerebral injuries of vascular traumatic nature with or without loss of consciousness & for treatment of degenerative damages & chronic cerebral vascular injuries in senile dementia. 4.2 Posology and Method of Administration The usually recommended dose of Citicoline is 500mg to 1000mg daily and can increase up to 2000mg. Elderly: No dosage adjustment is required in this patient population and the usually recommended adult dose can be administered. 4.3 Contraindications Hypersensitivity to citicoline or any other component of the formulation 4.4 Special Warnings and Special Precautions for Use: Citicoline may cause hypotension and in case necessary the hypotensive effect can be treated with corticosteroids or sympathomimetics. 4.5 Interaction with Other Medicinal Products and Other Forms of Interaction: Citicoline must not be used with medicines containing meclophenoxates (or centrophenoxine). Citicoline increases the effects of L-dopa. 4.6 Fertility, Pregnancy and Lactation There are no adequate and well controlled studies of citicoline during pregnancy and lactation. Citicoline should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
    [Show full text]
  • Alpha-GPC Introduced 2003
    Product Information Sheet – January 2015 Alpha-GPC Introduced 2003 What Is It? Are There Any Potential Drug Interactions? l-Alpha-glycerophophatidylcholine (GPC-choline, alpha-GPC) is a water- At this time, there are no known adverse reactions when taken in soluble phospholipid and neurotransmitter precursor naturally conjunction with medications. occurring in the body. Unlike most membrane phospholipids, alpha- GPC is water-soluble because it lacks the hydrophobic tail groups. Alpha-GPC Uses For Alpha-GPC each Caplique® Capsule contains v 0 • Memory And Cognitive Health: Alpha-GPC passes through the alpha-GPC (L-alpha-glycerophosphatidylcholine) ........................ 200 mg blood brain barrier providing a source of choline for acetylcholine other ingredients: glycerin, water, vegetarian Caplique® Capsule (cellulose, water) and phosphatidylcholine biosynthesis. By supporting cell membrane fluidity and integrity, phosphatidylcholine enhances Contains soy healthy neurotransmitter function and signal transduction. 6 Caplique® Capsules daily, in divided doses, with or Alpha-GPC may support healthy phospholipid turnover in the between meals. brain, helping to counteract age-related cellular breakdown of membrane phospholipids. Acetylcholine is a key neurotransmitter Caplique® Capsule is a registered trademark used by Pure Encapsulations in the brain supporting memory and learning. Optimal under license. phospholipid and acetylcholine levels support cognitive, mental Each Caplique® Capsule is preserved with a nitrogen bubble, which may give the and cerebrovascular health.* appearance of the capsule not being full. Contents may appear cloudy or thick and • Growth Hormone Support: Alpha-GPC has the ability to may settle or separate. potentiate growth hormone releasing hormone (GHRH), thereby supporting healthy growth hormone (GH) levels. The mechanism of support appears to involve increased cholinergic tone.* What Is The Source? Alpha-GPC is derived from highly purified soy lecithin.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0314884 A1 Cheyene (43) Pub
    US 20140314884A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0314884 A1 Cheyene (43) Pub. Date: Oct. 23, 2014 (54) HEALTH SUPPLEMENT USING GUARANA A61E36/53 (2006.01) EXTRACT A613 L/455 (2006.01) (52) U.S. Cl. (71) Applicant: Shaahin Cheyene, Venice, CA (US) CPC ............... A61K 36/534 (2013.01); A61K 36/53 (2013.01); A61K 36/16 (2013.01); A61K 36/41 (72) Inventor: Shaahin Cheyene, Venice, CA (US) (2013.01); A6 IK3I/522 (2013.01); A61 K 3I/714 (2013.01); A61 K3I/455 (2013.01); (21) Appl. No.: 13/751,151 A6 IK3I/221 (2013.01); A61 K3I/685 (2013.01); A61 K3I/198 (2013.01); A61 K (22) Filed: Apr. 17, 2013 31/4375 (2013.01); A61K 31/439 (2013.01): A6 IK3I/05 (2013.01) Publication Classification USPC .......................................................... 424/745 (51) Int. Cl. (57) ABSTRACT A6 IK36/534 (2006.01) The current invention is a Supplement made from a combina A6 IK 36/6 (2006.01) tion of herbs, vitamins, amino acids which in the preferred A6 IK 36/4I (2006.01) embodiment is a 100% vegetarian liquid capsules that are A6 IK3I/522 (2006.01) ingested allow for rapid absorption. The components of the A6 IK3I/714 (2006.01) Supplement can be mint or menthol Such as peppermint or A6 IK3I/05 (2006.01) spearmint, Methyl B12 or B12, Niacin, Guarana, Dimethy A6 IK3I/22 (2006.01) laminoethanol, Acetyl-L-carnitine or ALCAR, Ocimum A6 IK3I/685 (2006.01) tenuiflorum, one or more teas Such as green tea, white tea or A6 IK3I/98 (2006.01) black tea, Ginkgo, Rhodiola rosea, phosphatidylserine, A6 IK3I/4375 (2006.01) Tyrosine, L-Alpha Glycerylphosphorylcholine, Citicoline A6 IK3I/439 (2006.01) (INN), Huperzine A, and Vinpocetine.
    [Show full text]
  • Rat Brain Phosphatidyl-N,N-Dimethylethanolamine Is Rich in Polyunsaturated Fatty Acids
    Journal oj Neurochemistry Raven Press. New York 10 1985 International Society for Neurochemistry Rat Brain Phosphatidyl-N,N-Dimethylethanolamine Is Rich in Polyunsaturated Fatty Acids Mariateresa Tacconi and Richard J. Wurtman Laboratory of Neuroendocrine Regulation, Department of Applied Biological Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts, U.S.A. Abstract: Phosphatidyl - N,N - dimethylethanolamine analysis of its FAs (36.9 :t 1.8 g/g). The FAs in the PE (PDME), an intermediate in the formation of phosphati- and PC of rat brain synaptosomes were also analyzed; dylcholine (PC) by the sequential methylation of phos- too little PDME was present in synaptosomes to permit phatidylethanolamine (PE), was purified from rat brain similar analysis. The percentage of unsaturated FAs in- and its fatty acid (FA) composition compared with those synaptosomal PE was even higher (43.4 vs. 27.7) than that of brain PC and PE. The proportion of polyunsaturated in PE prepared from whole brain. Since synaptosomes fatty acids (PUFAs) in the PDME (29.8%) was similar to have a very high activity of phosphatidyl-N-methyltrans- that of PE (27.7%) and much greater than in PC (2.8%). ferase, the enzyme complex that methylates PE to form Like the PUFAs of PE, the major PUFAs found in PDME PC, this enzyme may serve, in nerve endings, to produce were arachidonic acid (20:4) and docosahexaenoic acid a particular pool of PC, rich in PUFAs, which may have (22:6). An isotopic method was developed to quantify the a distinct physiological function. Key Words: Fatty PDME purified from brain; a tritiated methyl group from acid composition - Phos phatid ylethanolamine-N -meth- CHJI was transferred to the PDME in the presence of yltransferase - Phosphatidyl - N,N - dimethylethanol- cyclohexylamine to form pH]PC, and the radioactivity of amine-Rat brain.
    [Show full text]
  • Biochemical Development of Surface Activity in Mammalian Lung. IV
    Pediat. Res. 6: 81-99 (1972) Developmental physiology lung hyaline membrane disease phospholipids infants respiratory distress syndrome lecithin surfactant Biochemical Development of Surface Activity in Mammalian Lung. IV. Pulmonary Lecithin Synthesis in the Human Fetus and Newborn and Etiology of the Respiratory Distress Syndrome Louis GLUCK1391, MARIE V. KULOVIGH, ARTHUR I. EIDELMAN, LEANDRO CORDERO, AND AIDA F. KHAZIN Department of Pediatrics, University of California, San Diego, School of Medicine, La Jolla, California, USA Extract The surface-active complex lining alveoli in normal lung lowers surface tension on ex- piration, thus preventing alveolar collapse. Surface activity follows a developmental timetable. Infants with idiopathic respiratory distress syndrome (RDS) almost ex- clusively are prematurely born, and their lungs lack adequate surface activity and are deficient in the principal surface-active component, lecithin. This deficiency implies that RDS is a "disease of development," with fetal and neonatal timetables for lecithin synthesis. The biosynthesis of lung lecithin in the living human infant was studied by examining phospholipids in lung effluent (pharyngeal aspirates, mucus), which have identical phospholipids to those in lung lavage (alveolar wash). The fatty acid esters of isolated lecithin and phosphatidyl dimethylethanolamine (PDME) were examined. The fi-carbon fatty acids are indicators of the primary pathways of synthesis of lecithin: (1) a preponderance of palmitic acid signifying cytidine diphosphate choline (CDP-choline) + D-a,{3-diglyceride -+lecithin (choline incorporation pathway) and (2) a preponder- ance of myristic acid signifying phosphatidyl ethanolamine (PE) + 2 CH3 —»• PDME + CHZ —> lecithin (methylation pathway). Fetal lung of 18 and 20 weeks showed slight incorporation by GDP-choline pathway, absence of PDME, and almost no methylation.
    [Show full text]
  • 1 Doctor Recommended for Ear Ringing Relief
    6/17/2019 Amazon.com: Premium Brain Function Supplement – Memory, Focus, Clarity – Nootropic Booster with DMAE, Bacopa Monnieri, L-Glutamine, Multi… Skip to main content All Try Prime brain supplement Deliver to EN Hello, Sign in 0 Guilford 06437 Today's Deals Your Amazon.com Gift Cards Account & Lists Orders Try Prime Cart ‹ Back to results Premium Brain Function Supplement – Memory, Focus, Clarity Price: $18.95 ($0.32 / Count) $19.95 $1.00 (5%) – Nootropic Booster with DMAE, Bacopa Monnieri, L- FREE Shipping on orders over $25—or get FREE Two-Day Shipping with Amazon Prime 1,425 customer reviews | 82 answered questions Extra $1.00 Off Coupon on first Subscribe and Save order only. Details In Stock. Sold by Arazo Nutrition and Fulfilled by Amazon. Subscribe & Save 5% 15% $18.95 ($0.32 / Count) Save 5% now and up to 15% on auto- deliveries. Learn more Get it Tuesday, Jun 18 One-time Purchase $19.95 ($0.33 / Count) 1+ Qty: Deliver every: 1 1 month ( Most common ) Subscribe now Add to List About the product ★ SCIENTIFICALLY FORMULATED – We carefully combined just the right amount of 41 ingredients into a premium formula designed to boost your focus, memory, concentration Other Sellers on Amazon 2 new from $19.95 and clarity. Perfect for college students, busy moms and aging seniors over 50. ★ FOCUS, MEMORY & CLARITY – Brain Plus is an all-natural Nootropic, formulated to help $22.95 ($0.38 / Count) & FREE Shipping on eligible Add to Cart support memory and cognition. The perfect blend of ingredients will increase oxygen and orders.
    [Show full text]
  • Présentation Powerpoint
    Table S1- List of metabolites analyzed with the AbsoluteIDQ p180 kit Metabolite Short name Biochemical Name Metabolite Short name Biochemical Name Class Class C0 L-Carnitine Ala Alanine C10 Decanoyl-L-carnitine Arg Arginine C10:1 Decenoyl-L-carnitine Asn Asparagine C10:2 Decadienyl-L-carnitine Asp Aspartate C12 Dodecanoyl-L-carnitine Cit Citrulline C12:1 Dodecenoyl-L-carnitine Gln Glutamine C12-DC Dodecanedioyl-L-carnitine Glu Glutamate C14 Tetradecanoyl-L-carnitine Gly Glycine C14:1 Tetradecenoyl-L-carnitine His Histidine C14:1-OH Hydroxytetradecenoyl-L-carnitine acids Ile Isoleucine C14:2 Tetradecadienyl-L-carnitine Leu Leucine C14:2-OH Hydroxytetradecadienyl-L-carnitine Lys Lysine C16 Hexadecanoyl-L-carnitine C16:1 Hexadecenoyl-L-carnitine Met Methionine C16:1-OH Hydroxyhexadecenoyl-L-carnitine Orn Ornithine C16:2 Hexadecadienyl-L-carnitine Amino Phe Phenylalanine C16:2-OH Hydroxyhexadecadienyl-L-carnitine Pro Proline Ser Serine carnitines C16-OH Hydroxyhexadecanoyl-L-carnitine - C18 Octadecanoyl-L-carnitine Thr Threonine L - C18:1 Octadecenoyl-L-carnitine Trp Tryptophan C18:1-OH Hydroxyoctadecenoyl-L-carnitine Tyr Tyrosine C18:2 Octadecadienyl-L-carnitine Val Valine acyl C2 Acetyl-L-carnitine Ac-Orn Acetylornithine C3 Propionyl-L-carnitine ADMA Asymmetric dimethylarginine & C3:1 Propenyl-L-carnitine SDMA Symmetric dimethylarginine C3-DC / C4-OH Malonyl-L-carnitine / Hydroxybutyryl-L- alpha-AAA alpha-Aminoadipic acid carnitine Carnosine Carnosine C3-DC-M / C5-OH Methylmalonyl-L-carnitine / Creatinine Creatinine Hydroxyvaleryl-L-carnitine
    [Show full text]
  • Nutritional and Herbal Therapies for Children and Adolescents
    Nutritional and Herbal Therapies for Children and Adolescents A Handbook for Mental Health Clinicians Nutritional and Herbal Therapies for Children and Adolescents A Handbook for Mental Health Clinicians George M. Kapalka Associate Professor, Monmouth University West Long Branch, NJ and Director, Center for Behavior Modifi cation Brick, NJ AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier Academic Press is an imprint of Elsevier 32 Jamestown Road, London NW1 7BY, UK 30 Corporate Drive, Suite 400, Burlington, MA 01803, USA 525 B Street, Suite 1900, San Diego, CA 92101-4495, USA Copyright © 2010 Elsevier Inc. All rights reserved No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher. Permissions may be sought directly from Elsevier’s Science & Technology Rights Department in Oxford, UK: phone (44) (0) 1865 843830; fax (44) (0) 1865 853333; email: [email protected]. Alternatively, visit the Science and Technology Books website at www.elsevierdirect.com/rights for further information Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material
    [Show full text]